^
    2d
    Evaluate the Safety and Clinical Activity of HH2853 (clinicaltrials.gov)
    P1/2, N=254, Recruiting, Haihe Biopharma Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    ARID1A (AT-rich interaction domain 1A) • BAP1 (BRCA1 Associated Protein 1)
    |
    ARID1A mutation • EZH2 mutation
    |
    HH2853
    2d
    X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov)
    P1, N=52, Recruiting, Immunolight, LLC | N=20 --> 52
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset)
    |
    HER-2 negative • ER negative
    |
    methoxsalen (X-PACT)
    3d
    Clinical study on the treatment of relapsed/refractory soft tissue sarcoma with liposome irinotecan combined with temozolomide and bevacizumab (ChiCTR2600117731)
    P=N/A, N=24, Not yet recruiting, The Second Affiliated Hospital of Zhejiang University School of Medicine; The Second Affiliated Hospital of Zhejiang University School of Medicine
    New trial
    |
    Avastin (bevacizumab) • temozolomide
    3d
    A Case Report on the Use of a Lumbar Artery Perforator Flap to Repair Postoperative Defects in Refractory Dermatofibrosarcoma Protuberans (ChiCTR2600116571)
    P=N/A, N=1, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University o
    New trial
    3d
    Optimization of Clinical Target Volume Delineation for Soft Tissue Sarcoma Radiotherapy Based on Recurrence Spatial Patterns: A Single-Center Real-World Study (ChiCTR2600116457)
    P=N/A, N=165, Not yet recruiting, Southern Medical University Southern Hospital; Southern Medical University Southern Hospital
    New trial
    3d
    Research on Precision Diagnosis and Treatment of Bone and Soft Tissue Sarcomas in Children (ChiCTR2500113908)
    P=N/A, N=1000, Recruiting, Beijing Childrens Hospital,Capital Medical University; Beijing Childrens Hospital,Capital Medical University
    New trial
    3d
    Umbrella Clinical Study of Precision Therapy for Bone and Soft Tissue Sarcomas Based on Different Targets (ChiCTR2500113769)
    P=N/A, N=50, Not yet recruiting, Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • BCL2 (B-cell CLL/lymphoma 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    HER-2 positive • HER-2 amplification
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    3d
    Efficacy and Safety of Epirubicin Plus Anlotinib Versus Epirubicin Plus Ifosfamide as Standard First-Line Regimens in Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma: A Randomized, Non-Comparative Study (ChiCTR2500113449)
    P2, N=58, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New P2 trial
    |
    Focus V (anlotinib) • ifosfamide • epirubicin
    3d
    An Exploratory Study of Liposomal Irinotecan (II) Combined with Apatinib in Soft Tissue Sarcoma After Failure of Standard Treatment (ChiCTR2600116806)
    P2, N=28, Recruiting, The First Medical Center of Chinese PLA General Hospital; The First Medical Center of Chinese PLA General Hospital
    New P2 trial
    |
    AiTan (rivoceranib)
    3d
    A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Radiation Dosimetry, Pharmacokinetics, and Preliminary Efficacy of ¹⁷⁷Lu-HX02 Injection in Patients with Advanced Malignant Solid Tumors (ChiCTR2600116425)
    P1, N=24, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.
    New P1 trial
    4d
    Describing the Mutational Characteristics of Myxofibrosarcoma: An AACR Project GENIE Analysis. (PubMed, Anticancer Res)
    As we enter the era of precision medicine, classifying cancers by molecular markers will become increasingly valuable. Our investigation enriches the literature by identifying novel mutations and mutations exclusive to certain demographic groups. These findings support a shift beyond histology toward molecularly informed diagnostics and pathway-directed therapeutic hypotheses for MFS. Next steps should validate candidate markers in independent cohorts and link genomic profiles to clinicopathologic features, disease course, and treatment response to improve clinical translation. These observations will help shape diagnostics and targeted therapies against MFS.
    Journal
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • NF1 (Neurofibromin 1) • ETV6 (ETS Variant Transcription Factor 6) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ATRX (ATRX Chromatin Remodeler) • NOTCH3 (Notch Receptor 3) • NCOR1 (Nuclear Receptor Corepressor 1) • FLCN (Folliculin) • ALOX12B (Arachidonate 12-Lipoxygenase) • MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4) • NCOA2 (Nuclear Receptor Coactivator 2) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A)
    |
    TP53 mutation • CDKN2A deletion
    4d
    Cytological, Immunocytochemical and Molecular Findings of Extraskeletal Round Cell Sarcomas in Paediatric Patients. (PubMed, Acta Cytol)
    Key messages Round cell sarcomas share many morphological similarities, so the differential diagnosis can be broad; however, subtle differences between tumours can aid the final diagnosis. Nevertheless, most round cell sarcomas require molecular studies for accurate classification, and cytological specimens are usually high quality material for such ancillary techniques.
    Review • Journal
    |
    BCOR (BCL6 Corepressor) • EWSR1 (EWS RNA Binding Protein 1)